Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 7/20 | 0.81 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.81 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.81 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.81 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.81 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.81 |
| ▸ | CHRNG | P07510 | 1/20 | 0.81 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.81 |
| ▸ | CHRND | Q07001 | 1/20 | 0.81 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905236 | 1.00 | CHRNA3 (0.81) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL3942452 | 1.00 | CHRNA3 (0.81) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7840031 | 0.99 | CHRNA3 (0.78) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8439827 | 0.99 | CHRNA3 (0.78) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL24154367 | 0.96 | CHRNA3 (0.78) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4318136 | 0.91 | LTA4H (0.67) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4318132 | 0.91 | LTA4H (0.67) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL905208 | 0.89 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL401138 | 0.89 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL676026 | 0.89 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0663912-B1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | claimed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | claimed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | claimed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | claimed |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | disclosed |
| EP-2983666-B1 | 2-HALO-5-ALKYNYL-PYRIDYL NICOTINIC LIGANDS | UNIV GEORGETOWN (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| US-9782404-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-10-10 | — | — | US | disclosed |
| US-9463190-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-11 | — | — | US | disclosed |
| US-9029557-B2 | Labeled A4B2 ligands and methods therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2009146031-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2006086068-A1 | LABELED ALPHA-4-BETA-2 LIGANDS AND METHODS THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-0663912-B1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | disclosed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | disclosed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | disclosed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNA3 6/4885CHRNB4 10/4885CHRNB2 9/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | CHRNA3 2130/4885CHRNB4 3293/4885CHRNB2 2793/4885 |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | BACE2, PSEN2, APP | CHRNA3 496/4885CHRNB4 131/4885CHRNB2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.